Hills Bank & Trust Co Increases Stock Holdings in Cencora, Inc. (NYSE:COR)

Hills Bank & Trust Co lifted its position in Cencora, Inc. (NYSE:COR) by 3.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 7,216 shares of the company’s stock after purchasing an additional 260 shares during the quarter. Hills Bank & Trust Co’s holdings in Cencora were worth $1,621,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. JFS Wealth Advisors LLC raised its holdings in shares of Cencora by 63.0% in the 4th quarter. JFS Wealth Advisors LLC now owns 119 shares of the company’s stock valued at $27,000 after acquiring an additional 46 shares in the last quarter. SBI Securities Co. Ltd. bought a new position in shares of Cencora in the fourth quarter worth approximately $30,000. Householder Group Estate & Retirement Specialist LLC raised its stake in Cencora by 85.2% in the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock valued at $33,000 after purchasing an additional 69 shares in the last quarter. Kentucky Trust Co bought a new stake in Cencora during the fourth quarter valued at approximately $33,000. Finally, WASHINGTON TRUST Co grew its stake in Cencora by 37.7% in the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company’s stock worth $38,000 after buying an additional 46 shares in the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Price Performance

COR stock opened at $258.09 on Friday. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40. The firm’s 50-day moving average price is $247.59 and its two-hundred day moving average price is $239.09. The stock has a market capitalization of $50.05 billion, a price-to-earnings ratio of 36.71, a PEG ratio of 1.31 and a beta of 0.51. Cencora, Inc. has a 12-month low of $214.77 and a 12-month high of $263.70.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, beating analysts’ consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. As a group, equities analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were paid a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.85%. The ex-dividend date was Friday, February 14th. Cencora’s payout ratio is 31.29%.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on COR. Mizuho assumed coverage on shares of Cencora in a research report on Wednesday, December 4th. They set an “outperform” rating and a $280.00 price objective on the stock. Evercore ISI lifted their price target on Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research note on Thursday, February 6th. Wells Fargo & Company increased their price target on shares of Cencora from $251.00 to $274.00 and gave the company an “equal weight” rating in a research report on Friday. StockNews.com raised shares of Cencora from a “hold” rating to a “buy” rating in a research note on Wednesday. Finally, JPMorgan Chase & Co. lifted their target price on shares of Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, Cencora currently has an average rating of “Moderate Buy” and a consensus target price of $280.20.

Insider Activity at Cencora

In other news, CAO Lazarus Krikorian sold 2,000 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $260.06, for a total value of $520,120.00. Following the completion of the transaction, the chief accounting officer now owns 20,154 shares of the company’s stock, valued at approximately $5,241,249.24. This represents a 9.03 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Silvana Battaglia sold 5,000 shares of Cencora stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $242.24, for a total value of $1,211,200.00. Following the sale, the executive vice president now owns 15,374 shares in the company, valued at $3,724,197.76. This represents a 24.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 13,648 shares of company stock worth $3,382,462 over the last quarter. Corporate insiders own 10.80% of the company’s stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.